

Marcel Spaargaren

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3896883/publications.pdf>

Version: 2024-02-01

97
papers

9,871
citations

57758

44
h-index

39675

94
g-index

101
all docs

101
docs citations

101
times ranked

12198
citing authors

#	ARTICLE	IF	CITATIONS
1	Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936. <i>Leukemia</i> , 2003, 17, 2257-2317.	7.2	2,788
2	The clinically active BTK inhibitor PCI-32765 targets B-cell receptor and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. <i>Blood</i> , 2012, 119, 2590-2594.	1.4	493
3	EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations. <i>Leukemia</i> , 2012, 26, 2159-2171.	7.2	409
4	Differential Interaction of the Ras Family GTP-binding Proteins H-Ras, Rap1A, and R-Ras with the Putative Effector Molecules Raf Kinase and Ral-Guanine Nucleotide Exchange Factor. <i>Journal of Biological Chemistry</i> , 1996, 271, 6794-6800.	3.4	298
5	Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 6122-6127.	7.1	293
6	Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936. <i>Leukemia</i> , 2007, 21, 207-214.	7.2	292
7	Bruton's Tyrosine Kinase and Phospholipase C β 2 Mediate Chemokine-Controlled B Cell Migration and Homing. <i>Immunity</i> , 2007, 26, 93-104.	14.3	262
8	Identification of the guanine nucleotide dissociation stimulator for Ral as a putative effector molecule of R-ras, H-ras, K-ras, and Rap.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1994, 91, 12609-12613.	7.1	251
9	Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. <i>Blood</i> , 2002, 99, 1405-1410.	1.4	235
10	Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2 Concerted Action BHM4 CT98-3936. <i>Leukemia</i> , 2007, 21, 215-221.	7.2	222
11	The B Cell Antigen Receptor Controls Integrin Activity through Btk and PLC β 2. <i>Journal of Experimental Medicine</i> , 2003, 198, 1539-1550.	8.5	211
12	Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation. <i>Cell Death and Differentiation</i> , 2005, 12, 637-648.	11.2	204
13	Heparan Sulfate-modified CD44 Promotes Hepatocyte Growth Factor/Scatter Factor-induced Signal Transduction through the Receptor Tyrosine Kinase c-Met. <i>Journal of Biological Chemistry</i> , 1999, 274, 6499-6506.	3.4	198
14	Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. <i>Blood</i> , 2013, 122, 2412-2424.	1.4	185
15	High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites. <i>Blood Cancer Journal</i> , 2013, 3, e139-e139.	6.2	164
16	Deletion of the WNT Target and Cancer Stem Cell Marker CD44 in Apc(Min/+) Mice Attenuates Intestinal Tumorigenesis. <i>Cancer Research</i> , 2008, 68, 3655-3661.	0.9	163
17	Lymphoma dissemination: the other face of lymphocyte homing. <i>Blood</i> , 2007, 110, 3102-3111.	1.4	157
18	The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. <i>Leukemia</i> , 2003, 17, 764-774.	7.2	145

#	ARTICLE	IF	CITATIONS
19	Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options. <i>Leukemia</i> , 2019, 33, 1063-1075.	7.2	119
20	Stem cell CD44v isoforms promote intestinal cancer formation in Apc(min) mice downstream of Wnt signaling. <i>Oncogene</i> , 2014, 33, 665-670.	5.9	116
21	Primary Follicular Lymphoma of the Small Intestine. <i>American Journal of Pathology</i> , 2003, 162, 105-113.	3.8	96
22	The hepatocyte growth factor/ met pathway in development, tumorigenesis, and B-cell differentiation. <i>Advances in Cancer Research</i> , 2000, 79, 39-90.	5.0	95
23	High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma. <i>Leukemia</i> , 2014, 28, 719-720.	7.2	91
24	FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF- κ B to promote survival of human B cells. <i>Blood</i> , 2014, 124, 3431-3440.	1.4	86
25	Factor VIIa/Tissue Factor-induced Signaling via Activation of Src-like Kinases, Phosphatidylinositol 3-Kinase, and Rac. <i>Journal of Biological Chemistry</i> , 2000, 275, 28750-28756.	3.4	85
26	Association of RACK1 and PKC ζ with the common β -chain of the IL-5/IL-3/GM-CSF receptor. <i>Oncogene</i> , 1999, 18, 5126-5130.	5.9	81
27	Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma. <i>Blood</i> , 2006, 107, 760-768.	1.4	80
28	Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy. <i>Blood</i> , 2015, 125, 2306-2309.	1.4	79
29	Rab5 Induces Rac-independent Lamellipodia Formation and Cell Migration. <i>Molecular Biology of the Cell</i> , 1999, 10, 3239-3250.	2.1	77
30	Human sprouty 4, a new ras antagonist on 5q31, interacts with the dual specificity kinase TESK1. <i>FEBS Journal</i> , 2002, 269, 2546-2556.	0.2	76
31	Expression of c-Met and Heparan-Sulfate Proteoglycan Forms of CD44 in Colorectal Cancer. <i>American Journal of Pathology</i> , 2000, 157, 1563-1573.	3.8	75
32	Syndecan-1 promotes Wnt/ β -catenin signaling in multiple myeloma by presenting Wnts and R-spondins. <i>Blood</i> , 2018, 131, 982-994.	1.4	68
33	The Ras-related protein R-ras interacts directly with Raf-1 in a GTP-dependent manner. <i>Biochemical Journal</i> , 1994, 300, 303-307.	3.7	62
34	c-Cbl Is Involved in Met Signaling in B Cells and Mediates Hepatocyte Growth Factor-Induced Receptor Ubiquitination. <i>Journal of Immunology</i> , 2002, 169, 3793-3800.	0.8	57
35	Characterization and identification of an epidermal-growth-factor-activated phospholipase A2. <i>Biochemical Journal</i> , 1992, 287, 37-43.	3.7	56
36	<i>MYD88</i> mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis. <i>Haematologica</i> , 2020, 105, 424-434.	3.5	55

#	ARTICLE	IF	CITATIONS
37	Multiple myeloma cells catalyze hepatocyte growth factor (HGF) activation by secreting the serine protease HGF-activator. <i>Blood</i> , 2004, 104, 2172-2175.	1.4	54
38	Tubular epithelial syndecan-1 maintains renal function in murine ischemia/reperfusion and human transplantation. <i>Kidney International</i> , 2012, 81, 651-661.	5.2	54
39	Epidermal Growth Factor (EGF) Induces Serine Phosphorylation-Dependent Activation and Calcium-Dependent Translocation of the Cytosolic Phospholipase A2. <i>FEBS Journal</i> , 1995, 231, 593-601.	0.2	53
40	Transcriptional Silencing of the Wnt-Antagonist Dickkopf-1 (DKK1) by Promoter Methylation Unleashes Aberrant Wnt Signaling In Advanced Multiple Myeloma. <i>Blood</i> , 2010, 116, 1919-1919.	1.4	53
41	Targeting EXT1 reveals a crucial role for heparan sulfate in the growth of multiple myeloma. <i>Blood</i> , 2010, 115, 601-604.	1.4	50
42	Infection and transmission of SARS-CoV-2 depend on heparan sulfate proteoglycans. <i>EMBO Journal</i> , 2021, 40, e106765.	7.8	50
43	Disruption of heparan sulfate proteoglycan conformation perturbs B-cell maturation and APRIL-mediated plasma cell survival. <i>Blood</i> , 2011, 117, 6162-6171.	1.4	48
44	MET Signaling Mediates Intestinal Crypt-Villus Development, Regeneration, and Adenoma Formation and Is Promoted by Stem Cell CD44 Isoforms. <i>Gastroenterology</i> , 2017, 153, 1040-1053.e4.	1.3	48
45	Heparan sulfate proteoglycans in the control of B cell development and the pathogenesis of multiple myeloma. <i>FEBS Journal</i> , 2013, 280, 2180-2193.	4.7	47
46	Regulation of Cytokine Signaling by B Cell Antigen Receptor and Cd40-Controlled Expression of Heparan Sulfate Proteoglycans. <i>Journal of Experimental Medicine</i> , 2000, 192, 1115-1124.	8.5	46
47	The small GTPase Ral mediates SDF-1-induced migration of B cells and multiple myeloma cells. <i>Blood</i> , 2008, 111, 3364-3372.	1.4	43
48	The forkhead transcription factor FOXP1 represses human plasma cell differentiation. <i>Blood</i> , 2015, 126, 2098-2109.	1.4	42
49	Illegitimate WNT Pathway Activation by β^2 -Catenin Mutation or Autocrine Stimulation in T-Cell Malignancies. <i>Cancer Research</i> , 2008, 68, 6969-6977.	0.9	41
50	Transcriptional Silencing of the Wnt-Antagonist DKK1 by Promoter Methylation Is Associated with Enhanced Wnt Signaling in Advanced Multiple Myeloma. <i>PLoS ONE</i> , 2012, 7, e30359.	2.5	41
51	The hypoxia target adrenomedullin is aberrantly expressed in multiple myeloma and promotes angiogenesis. <i>Leukemia</i> , 2013, 27, 1729-1737.	7.2	41
52	Tubulointerstitial heparan sulfate proteoglycan changes in human renal diseases correlate with leukocyte influx and proteinuria. <i>American Journal of Physiology - Renal Physiology</i> , 2008, 294, F253-F263.	2.7	39
53	Hepatocyte growth factor triggers signaling cascades mediating vascular smooth muscle cell migration. <i>Biochemical and Biophysical Research Communications</i> , 2002, 298, 80-86.	2.1	37
54	Aberrantly expressed LGR4 empowers Wnt signaling in multiple myeloma by hijacking osteoblast-derived R-spondins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 376-381.	7.1	37

#	ARTICLE	IF	CITATIONS
55	Interaction of Epidermal growth factor receptors with the cytoskeleton is related to receptor clustering. <i>Journal of Cellular Physiology</i> , 1990, 145, 365-375.	4.1	36
56	N-cadherin-mediated interaction with multiple myeloma cells inhibits osteoblast differentiation. <i>Haematologica</i> , 2011, 96, 1653-1661.	3.5	36
57	Loss of CYLD expression unleashes Wnt signaling in multiple myeloma and is associated with aggressive disease. <i>Oncogene</i> , 2017, 36, 2105-2115.	5.9	34
58	The B Cell Antigen Receptor Controls AP-1 and NFAT Activity through Ras-Mediated Activation of Ral. <i>Journal of Immunology</i> , 2007, 178, 1405-1414.	0.8	31
59	Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenstrom macroglobulinemia. <i>Haematologica</i> , 2016, 101, e111-e115.	3.5	30
60	BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future. <i>Oncogene</i> , 2015, 34, 2426-2436.	5.9	29
61	The HGF/MET pathway as target for the treatment of multiple myeloma and B-cell lymphomas. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2010, 1806, 208-219.	7.4	28
62	Cell lines generated from a chronic lymphocytic leukemia mouse model exhibit constitutive Btk and Akt signaling. <i>Oncotarget</i> , 2017, 8, 71981-71995.	1.8	27
63	WNT signaling controls expression of pro-apoptotic BOK and BAX in intestinal cancer. <i>Biochemical and Biophysical Research Communications</i> , 2011, 406, 1-6.	2.1	26
64	Hepatocyte growth factor/MET and CD44 in colorectal cancer: partners in tumorigenesis and therapy resistance. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1874, 188437.	7.4	26
65	Impaired Lymphoid Organ Development in Mice Lacking the Heparan Sulfate Modifying Enzyme Glucuronyl C5-Epimerase. <i>Journal of Immunology</i> , 2010, 184, 3656-3664.	0.8	25
66	Follicular Dendritic Cells Catalyze Hepatocyte Growth Factor (HGF) Activation in the Germinal Center Microenvironment by Secreting the Serine Protease HGF Activator. <i>Journal of Immunology</i> , 2005, 175, 2807-2813.	0.8	24
67	Stimulated plasmacytoid dendritic cells impair human T-cell development. <i>Blood</i> , 2006, 108, 3792-3800.	1.4	24
68	CD44 Expression in Intestinal Epithelium and Colorectal Cancer Is Independent of p53 Status. <i>PLoS ONE</i> , 2013, 8, e72849.	2.5	23
69	AKT signaling restrains tumor suppressive functions of FOXO transcription factors and GSK3 kinase in multiple myeloma. <i>Blood Advances</i> , 2020, 4, 4151-4164.	5.2	20
70	R-Ras Alters Ca ²⁺ Homeostasis by Increasing the Ca ²⁺ Leak across the Endoplasmic Reticular Membrane. <i>Journal of Biological Chemistry</i> , 2003, 278, 13672-13679.	3.4	18
71	The small FOXP1 isoform predominantly expressed in activated B cell-like diffuse large B-cell lymphoma and full-length FOXP1 exert similar oncogenic and transcriptional activity in human B cells. <i>Haematologica</i> , 2017, 102, 573-583.	3.5	18
72	The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells. <i>Leukemia</i> , 2016, 30, 337-345.	7.2	17

#	ARTICLE	IF	CITATIONS
73	The CXCL12gamma chemokine immobilized by heparan sulfate on stromal niche cells controls adhesion and mediates drug resistance in multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2021, 14, 11.	17.0	15
74	MET Signaling Overcomes Epidermal Growth Factor Receptor Inhibition in Normal and Colorectal Cancer Stem Cells Causing Drug Resistance. <i>Gastroenterology</i> , 2019, 157, 1153-1155.e1.	1.3	14
75	Identification of the SRC-family tyrosine kinase HCK as a therapeutic target in mantle cell lymphoma. <i>Leukemia</i> , 2021, 35, 881-886.	7.2	14
76	Syndecan-1 and stromal heparan sulfate proteoglycans: key moderators of plasma cell biology and myeloma pathogenesis. <i>Blood</i> , 2021, 137, 1713-1718.	1.4	14
77	The anaphase-promoting complex/cyclosome: a new promising target in diffuse large B-cell lymphoma and mantle cell lymphoma. <i>British Journal of Cancer</i> , 2019, 120, 1137-1146.	6.4	12
78	Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations. <i>Blood Cancer Journal</i> , 2014, 4, e266-e266.	6.2	11
79	Antibody-induced activation of the epidermal growth factor receptor tyrosine kinase requires the presence of detergent. <i>Biochemical and Biophysical Research Communications</i> , 1990, 171, 882-889.	2.1	10
80	Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma. <i>Leukemia</i> , 2022, 36, 2165-2176.	7.2	8
81	Possible Mechanisms Of Resistance To The Novel BH3-Mimetic ABT-199 In In Vitro Lymph Node Models Of CLL – The Role Of Abl and Btk. <i>Blood</i> , 2013, 122, 4188-4188.	1.4	6
82	Redirecting T-cell Activity with Anti-BCMA/Anti-CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia and Other B-cell Lymphomas. <i>Cancer Research Communications</i> , 2022, 2, 330-341.	1.7	6
83	Targeting cell adhesion and homing as strategy to cure Waldenström's macroglobulinemia. <i>Best Practice and Research in Clinical Haematology</i> , 2016, 29, 161-168.	1.7	5
84	Immune evasion in primary testicular and central nervous system lymphomas: HLA loss rather than PD-L1/PD-L2 alterations. <i>Blood</i> , 2021, 138, 1194-1197.	1.4	5
85	Lymphoma spread? Target CD47-SIRPα!. <i>Blood</i> , 2011, 118, 4762-4764.	1.4	4
86	A loss-of-adhesion CRISPR-Cas9 screening platform to identify cell adhesion-regulatory proteins and signaling pathways. <i>Nature Communications</i> , 2022, 13, 2136.	12.8	4
87	Instant conditional transgenesis in the mouse hematopoietic compartment. <i>Journal of Immunological Methods</i> , 2008, 339, 259-263.	1.4	3
88	Combined Inhibition of mTOR and DNA-PK Blocks Survival, Adhesion, Proliferation and Chemoresistance in Primary Chronic Lymphocytic Leukemia (CLL) Cells. <i>Blood</i> , 2014, 124, 1981-1981.	1.4	3
89	Mapping the Targets of Dasatinib in Chronic Lymphocytic Leukemia Reveals Distinct Roles for Abl and Btk in Drug Resistance and Adhesion, and Explains Clinical Effects On Lymph Node Reduction. <i>Blood</i> , 2012, 120, 3900-3900.	1.4	2
90	Ibrutinib for AML? Check CD117 (KIT)!. <i>Lancet Haematology</i> , 2015, 2, e180-e181.	4.6	1

#	ARTICLE	IF	CITATIONS
91	Targeting EXT-1 Reveals a Crucial Role of Heparan Sulfate in the Growth of Multiple Myeloma.. Blood, 2009, 114, 1830-1830.	1.4	1
92	Egress of CD19+CD5+ Cells Into Peripheral Blood Following Treatment with the Bruton Tyrosine Kinase Inhibitor, PCI-32765, in Mantle Cell Lymphoma Patients. Blood, 2011, 118, 954-954.	1.4	1
93	Combined Inhibition of Phosphatidylinositol 3-Kinase (PI3K) Isoform β and γ By the Pan-Class I PI3K Inhibitor SAR245409 (XL765) in Primary Chronic Lymphocytic Leukemia Cells Blocks Survival, Adhesion and Proliferation. Blood, 2014, 124, 4691-4691.	1.4	1
94	Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e108.	0.4	0
95	Syndecan-1 and stromal HSPGs: key moderators of communication between myeloma plasma cells and the bone marrow niche. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e96-e97.	0.4	0
96	Dimerization Activates the Epidermal Growth Factor Receptor Tyrosine Kinase. , 1991, , 45-58.		0
97	General Mechanistic Patterns of Signal Transduction Across Membranes. , 0, , 1-59.		0